

# SAFETY DATA SHEET



## Fidaxomicin Solid Formulation

Version 3.0      Revision Date: 14.04.2025      SDS Number: 4750801-00012      Date of last issue: 06.04.2024  
Date of first issue: 15.08.2019

---

### Section 1: Identification

**Product identifier** : Fidaxomicin Solid Formulation

**Recommended use of the chemical and restrictions on use**

Recommended use : Pharmaceutical  
Restrictions on use : Not applicable

**Manufacturer or supplier's details**

Company : MSD  
Address : 50 Tuas West Drive  
Singapore - Singapore 638408  
Telephone : +1-908-740-4000  
Emergency telephone number : 65 6697 2111 (24/7/365)  
E-mail address : EHSDATASTEWARD@msd.com

---

### Section 2: Hazard identification

**Classification of the substance or mixture**

Acute toxicity (Oral) : Category 4

**GHS Label elements, including precautionary statements**

Hazard pictograms : 

Signal word : Warning

Hazard statements : H302 Harmful if swallowed.

Precautionary statements : **Prevention:**  
P264 Wash skin thoroughly after handling.  
P270 Do not eat, drink or smoke when using this product.  
**Response:**  
P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/ doctor if you feel unwell. Rinse mouth.  
**Disposal:**  
P501 Dispose of contents/ container to an approved waste disposal plant.

# SAFETY DATA SHEET



## Fidaxomicin Solid Formulation

Version 3.0 Revision Date: 14.04.2025 SDS Number: 4750801-00012 Date of last issue: 06.04.2024 Date of first issue: 15.08.2019

---

### Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.  
Contact with dust can cause mechanical irritation or drying of the skin.  
May form explosive dust-air mixture during processing, handling or other means.

## Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

### Components

Chemical name	CAS-No.	Concentration (% w/w)
Fidaxomicin	873857-62-6	>= 50 -< 70
Cellulose	9004-34-6	>= 20 -< 30
Sodium benzoate	532-32-1	>= 1 -< 10
Citric acid	77-92-9	>= 1 -< 10

## Section 4: First-aid measures

### Description of necessary first-aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.

When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap.

Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting unless directed to do so by medical personnel.

Get medical attention.

Rinse mouth thoroughly with water.

Never give anything by mouth to an unconscious person.

### Most important symptoms and effects, both acute and delayed

Risks : Contact with dust can cause mechanical irritation or drying of the skin.

Dust contact with the eyes can lead to mechanical irritation.

Harmful if swallowed.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

### Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

# SAFETY DATA SHEET



## Fidaxomicin Solid Formulation

Version 3.0      Revision Date: 14.04.2025      SDS Number: 4750801-00012      Date of last issue: 06.04.2024  
Date of first issue: 15.08.2019

---

### Section 5: Fire-fighting measures

#### Extinguishing media

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

#### Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides  
Metal oxides  
Chlorine compounds

#### Special protective actions for fire-fighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

---

### Section 6: Accidental release measures

#### Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

#### Environmental precautions

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

#### Methods and materials for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).

# SAFETY DATA SHEET



## Fidaxomicin Solid Formulation

Version  
3.0

Revision Date:  
14.04.2025

SDS Number:  
4750801-00012

Date of last issue: 06.04.2024  
Date of first issue: 15.08.2019

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

---

### Section 7: Handling and storage

#### Precautions for safe handling

Technical measures	: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation	: Use only with adequate ventilation.
Advice on safe handling	: Do not breathe dust. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment.
Hygiene measures	: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

#### Conditions for safe storage, including any incompatibilities

Conditions for safe storage	: Keep in properly labelled containers. Store in accordance with the particular national regulations.
Materials to avoid	: Do not store with the following product types: Strong oxidizing agents

**Fidaxomicin Solid Formulation**Version  
3.0Revision Date:  
14.04.2025SDS Number:  
4750801-00012Date of last issue: 06.04.2024  
Date of first issue: 15.08.2019

---

**Section 8: Exposure controls/personal protection****Control parameters****Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Fidaxomicin	873857-62-6	TWA	200 µg/m <sup>3</sup> (OEB 2)	Internal
Cellulose	9004-34-6	PEL (long term)	10 mg/m <sup>3</sup>	SG OEL
		TWA	10 mg/m <sup>3</sup>	ACGIH
Sodium benzoate	532-32-1	TWA (Inhal- able particu- late matter)	2.5 mg/m <sup>3</sup>	ACGIH

**Appropriate engineering control measures**

: Use feasible engineering controls to minimize exposure to compound.  
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

**Individual protection measures, such as personal protective equipment (PPE)**

Eye/face protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin protection : Work uniform or laboratory coat.

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection : Chemical-resistant gloves

Material

---

**Section 9: Physical and chemical properties**

Appearance : granules

Colour : White to light yellow

Odour : No data available

Odour Threshold : No data available

pH : No data available

# SAFETY DATA SHEET



## Fidaxomicin Solid Formulation

Version 3.0      Revision Date: 14.04.2025      SDS Number: 4750801-00012      Date of last issue: 06.04.2024  
Date of first issue: 15.08.2019

---

Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	Not applicable
Relative vapour density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics		
Particle size	:	No data available

# SAFETY DATA SHEET



## Fidaxomicin Solid Formulation

Version 3.0 Revision Date: 14.04.2025 SDS Number: 4750801-00012 Date of last issue: 06.04.2024 Date of first issue: 15.08.2019

---

### Section 10: Stability and reactivity

Reactivity	: Not classified as a reactivity hazard.
Chemical stability	: Stable under normal conditions.
Possibility of hazardous reactions	: May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	: Heat, flames and sparks. Avoid dust formation.
Incompatible materials	: Oxidizing agents
Hazardous decomposition products	: No hazardous decomposition products are known.

---

### Section 11: Toxicological information

Information on likely routes of exposure	: Inhalation Skin contact Ingestion Eye contact
--	--

#### Acute toxicity

Harmful if swallowed.

#### Product:

Acute oral toxicity	: Acute toxicity estimate: 875.04 mg/kg Method: Calculation method
---------------------	---

#### Components:

##### **Fidaxomicin:**

Acute oral toxicity	: LD50 (Rat): > 1,000 mg/kg LD50 (Dog): > 120 mg/kg
Acute toxicity (other routes of administration)	: LD50 (Rat): 200 mg/kg Application Route: Intravenous

##### **Cellulose:**

Acute oral toxicity	: LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity	: LC50 (Rat): > 5.8 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	: LD50 (Rabbit): > 2,000 mg/kg

##### **Sodium benzoate:**

Acute oral toxicity	: LD50 (Rat): > 2,000 mg/kg Assessment: The substance or mixture has no acute oral toxicity
---------------------	--

**Fidaxomicin Solid Formulation**

Version 3.0      Revision Date: 14.04.2025      SDS Number: 4750801-00012      Date of last issue: 06.04.2024  
Date of first issue: 15.08.2019

---

**Acute dermal toxicity** : LD50 (Rabbit): > 2,000 mg/kg  
Remarks: Based on data from similar materials

**Citric acid:**

**Acute oral toxicity** : LD50 (Mouse): 5,400 mg/kg

**Acute dermal toxicity** : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 402  
Assessment: The substance or mixture has no acute dermal toxicity

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Sodium benzoate:**

**Species** : Rabbit  
**Method** : OECD Test Guideline 404  
**Result** : No skin irritation

**Citric acid:**

**Species** : Rabbit  
**Method** : OECD Test Guideline 404  
**Result** : No skin irritation

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Sodium benzoate:**

**Species** : Rabbit  
**Result** : Irritation to eyes, reversing within 21 days  
**Method** : OECD Test Guideline 405

**Citric acid:**

**Species** : Rabbit  
**Result** : Irritation to eyes, reversing within 21 days  
**Method** : OECD Test Guideline 405

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Fidaxomicin Solid Formulation**Version  
3.0Revision Date:  
14.04.2025SDS Number:  
4750801-00012Date of last issue: 06.04.2024  
Date of first issue: 15.08.2019**Components:****Sodium benzoate:**

Test Type	:	Local lymph node assay (LLNA)
Exposure routes	:	Skin contact
Species	:	Mouse
Result	:	negative
Remarks	:	Based on data from similar materials

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Fidaxomicin:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: Chromosome aberration test in vitro Test system: Chinese hamster ovary cells Result: positive
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Rat Application Route: Intravenous Result: negative
		Test Type: comet assay Species: Rat Result: negative

**Cellulose:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: In vitro mammalian cell gene mutation test Result: negative
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Ingestion Result: negative

**Sodium benzoate:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: Chromosome aberration test in vitro Result: positive

**Fidaxomicin Solid Formulation**

Version 3.0      Revision Date: 14.04.2025      SDS Number: 4750801-00012      Date of last issue: 06.04.2024  
Date of first issue: 15.08.2019

---

**Genotoxicity in vivo**

: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)  
Species: Rat  
Application Route: Ingestion  
Result: negative

**Citric acid:**

**Genotoxicity in vitro**

: Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: in vitro micronucleus test  
Result: positive

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

**Genotoxicity in vivo**

: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)  
Species: Rat  
Application Route: Ingestion  
Result: negative

**Carcinogenicity**

Not classified based on available information.

**Components:****Cellulose:**

**Species** : Rat  
**Application Route** : Ingestion  
**Exposure time** : 72 weeks  
**Result** : negative

**Sodium benzoate:**

**Species** : Rat  
**Application Route** : Ingestion  
**Exposure time** : 24 month(s)  
**Result** : negative

**Reproductive toxicity**

Not classified based on available information.

**Components:****Fidaxomicin:**

**Effects on fertility** : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Intravenous injection  
Fertility: NOAEL: 6.3 mg/kg body weight

# SAFETY DATA SHEET



## Fidaxomicin Solid Formulation

Version 3.0      Revision Date: 14.04.2025      SDS Number: 4750801-00012      Date of last issue: 06.04.2024  
Date of first issue: 15.08.2019

Effects on foetal development	: Test Type: Embryo-foetal development Species: Rat Application Route: Intravenous injection Developmental Toxicity: NOAEL: 12.6 mg/kg body weight Remarks: No significant adverse effects were reported
	Test Type: Embryo-foetal development Species: Rabbit Application Route: Intravenous injection Developmental Toxicity: NOAEL: 7 mg/kg body weight Remarks: No significant adverse effects were reported

### Cellulose:

Effects on fertility	: Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative
Effects on foetal development	: Test Type: Fertility/early embryonic development Species: Rat Application Route: Ingestion Result: negative

### Sodium benzoate:

Effects on fertility	: Test Type: Four-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative Remarks: Based on data from similar materials
Effects on foetal development	: Test Type: Embryo-foetal development Species: Rat Application Route: Ingestion Result: negative

### Citric acid:

Effects on foetal development	: Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative
-------------------------------	---

### STOT - single exposure

Not classified based on available information.

### Components:

#### Citric acid:

Assessment	: May cause respiratory irritation.
------------	-------------------------------------

**Fidaxomicin Solid Formulation**

Version 3.0      Revision Date: 14.04.2025      SDS Number: 4750801-00012      Date of last issue: 06.04.2024  
Date of first issue: 15.08.2019

---

**STOT - repeated exposure**

Not classified based on available information.

**Repeated dose toxicity****Components:****Fidaxomicin:**

Species	:	Rat
NOAEL	:	90 mg/kg
Application Route	:	Oral
Exposure time	:	28 D
Remarks	:	No significant adverse effects were reported
Species	:	Rat
NOAEL	:	62.5 mg/kg
Application Route	:	Intravenous
Exposure time	:	14 D
Species	:	Dog
NOAEL	:	9,600 mg/kg
Application Route	:	Oral
Exposure time	:	3 M
Symptoms	:	Vomiting
Remarks	:	No significant adverse effects were reported
Species	:	Monkey
NOAEL	:	90 mg/kg
Application Route	:	Oral
Exposure time	:	28 D
Remarks	:	No significant adverse effects were reported
Species	:	Juvenile rat
NOAEL	:	200 mg/kg
Application Route	:	Oral
Exposure time	:	28 D
Remarks	:	No significant adverse effects were reported

**Cellulose:**

Species	:	Rat
NOAEL	:	>= 9,000 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days

**Sodium benzoate:**

Species	:	Rat
NOAEL	:	1,000 mg/kg
Application Route	:	Ingestion
Exposure time	:	24 Months

**Citric acid:**

**Fidaxomicin Solid Formulation**

Version 3.0 Revision Date: 14.04.2025 SDS Number: 4750801-00012 Date of last issue: 06.04.2024 Date of first issue: 15.08.2019

---

Species	:	Rat
NOAEL	:	4,000 mg/kg
LOAEL	:	8,000 mg/kg
Application Route	:	Ingestion
Exposure time	:	10 Days

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Fidaxomicin:**

Ingestion	:	Symptoms: Abdominal pain, Nausea, Vomiting, constipation
-----------	---	--

**Section 12: Ecological information****Toxicity****Components:****Fidaxomicin:**

Toxicity to algae/aquatic plants	:	EC50 (Anabaena flos-aquae (cyanobacterium)): > 18.4 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
		NOEC (Anabaena flos-aquae (cyanobacterium)): 5.8 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
Toxicity to fish (Chronic toxicity)	:	NOEC (Pimephales promelas (fathead minnow)): 8.91 mg/l Exposure time: 32 d Method: OECD Test Guideline 210 Remarks: No toxicity at the limit of solubility
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC (Daphnia magna (Water flea)): 19.6 mg/l Exposure time: 21 d Method: OECD Test Guideline 211
Toxicity to microorganisms	:	EC50: > 50 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209
		NOEC: 5.9 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209

# SAFETY DATA SHEET



## Fidaxomicin Solid Formulation

Version 3.0      Revision Date: 14.04.2025      SDS Number: 4750801-00012      Date of last issue: 06.04.2024  
Date of first issue: 15.08.2019

---

### **Cellulose:**

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l  
Exposure time: 48 h  
Remarks: Based on data from similar materials

### **Sodium benzoate:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 484 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l  
Exposure time: 96 h

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 32 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

### **Citric acid:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 1,535 mg/l  
Exposure time: 24 h

### **Persistence and degradability**

#### **Components:**

##### **Cellulose:**

Biodegradability : Result: Readily biodegradable.

##### **Sodium benzoate:**

Biodegradability : Result: Readily biodegradable.  
Biodegradation: 75 %  
Exposure time: 28 d

##### **Citric acid:**

Biodegradability : Result: Readily biodegradable.  
Biodegradation: 97 %  
Exposure time: 28 d  
Method: OECD Test Guideline 301B

# SAFETY DATA SHEET



## Fidaxomicin Solid Formulation

Version 3.0      Revision Date: 14.04.2025      SDS Number: 4750801-00012      Date of last issue: 06.04.2024  
Date of first issue: 15.08.2019

---

### Bioaccumulative potential

#### Components:

##### **Fidaxomicin:**

Partition coefficient: n-octanol/water : log Pow: 4.4

##### **Sodium benzoate:**

Partition coefficient: n-octanol/water : log Pow: 1.88

##### **Citric acid:**

Partition coefficient: n-octanol/water : log Pow: -1.72

### Mobility in soil

#### Components:

##### **Fidaxomicin:**

Distribution among environmental compartments : log Koc: 0.80

### Other adverse effects

No data available

---

## Section 13: Disposal considerations

### Disposal methods

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

## Section 14: Transport information

### International Regulations

#### **UNRTDG**

UN number : Not applicable  
UN proper shipping name : Not applicable  
Transport hazard class(es) : Not applicable  
Subsidiary risk : Not applicable  
Packing group : Not applicable  
Labels : Not applicable  
Environmentally hazardous : no

#### **IATA-DGR**

UN/ID No. : Not applicable  
UN proper shipping name : Not applicable  
Transport hazard class(es) : Not applicable  
Subsidiary risk : Not applicable

# SAFETY DATA SHEET



## Fidaxomicin Solid Formulation

Version 3.0      Revision Date: 14.04.2025      SDS Number: 4750801-00012      Date of last issue: 06.04.2024  
Date of first issue: 15.08.2019

---

Packing group : Not applicable  
Labels : Not applicable  
Packing instruction (cargo aircraft) : Not applicable  
Packing instruction (passenger aircraft) : Not applicable

### IMDG-Code

UN number : Not applicable  
UN proper shipping name : Not applicable  
Transport hazard class(es) : Not applicable  
Subsidiary risk : Not applicable  
Packing group : Not applicable  
Labels : Not applicable  
EmS Code : Not applicable  
Marine pollutant : Not applicable

### Transport in bulk according to IMO instruments

Not applicable for product as supplied.

### Special precautions for user

Not applicable

---

## Section 15: Regulatory information

### Safety, health and environmental regulations specific for the product in question

Workplace Safety and Health Act and Workplace Safety and Health (General Provisions) Regulations: This product is subject to the requirements in the Act/Regulations.

Environmental Protection and Management Act and : Not applicable  
Environmental Protection and Management (Hazardous Substances) Regulations  
Fire Safety (Petroleum and Flammable Materials) : Not applicable  
Regulations

### The components of this product are reported in the following inventories:

AICS : not determined  
DSL : not determined  
IECSC : not determined

---

## Section 16: Other information

Revision Date : 14.04.2025

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

# SAFETY DATA SHEET



## Fidaxomicin Solid Formulation

---

Version 3.0	Revision Date: 14.04.2025	SDS Number: 4750801-00012	Date of last issue: 06.04.2024 Date of first issue: 15.08.2019
----------------	------------------------------	------------------------------	---

---

Date format : dd.mm.yyyy

### Full text of other abbreviations

ACGIH	: USA. ACGIH Threshold Limit Values (TLV)
SG OEL	: Singapore. Workplace Safety and Health (General Provisions) Regulations - First Schedule Permissible Exposure Limits of Toxic Substances.
ACGIH / TWA	: 8-hour, time-weighted average
SG OEL / PEL (long term)	: Permissible Exposure Level (PEL) Long Term

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECL - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

# SAFETY DATA SHEET



## Fidaxomicin Solid Formulation

---

Version 3.0	Revision Date: 14.04.2025	SDS Number: 4750801-00012	Date of last issue: 06.04.2024
			Date of first issue: 15.08.2019

---

SG / EN